ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0124

Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Abstract Number: 0125

Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab
Abstract Number: 0126

Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?
Abstract Number: 0127

The Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study) Supports Multidimensional Disease Symptomatology with High Levels of Pain and Fatigue, and Low Levels of Function
Abstract Number: 0128

Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015
Abstract Number: 0129

Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
Abstract Number: 0130

Three Chinese Pedigrees of A20 Haploinsufficiency
Abstract Number: 0131

Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study
Abstract Number: 0132

Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre
Abstract Number: 0133

Retention Rate of Targeted Therapies in Erdheim-Chester Disease
Abstract Number: 0134

Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A
Abstract Number: 0135

Janus Kinase Inhibitors in Severe and Refractory Inflammatory Ocular Pathology. Cases Reports and Literature Review
Abstract Number: 0136

Sarcoidosis Incidence After mTOR Inhibitor Treatment
Abstract Number: 0137

Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study
Abstract Number: 0138

Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].